Fruquintinib in the Cross-line Treatment of Refractory mCRC

ABSTRACT: This is a real-world study. Patients with metastatic colorectal cancer who have progressed (PD) after third-line treatment with fruquintinib combined with PD-1 inhibitors will receive fruquintinib combined with TAS-102 as fourth-line therapy. The objective of this study was to observe the efficacy and safety of cross-line（from third to fourth line）treatment with fruquinitinib.

DISEASE(S): Fruquintinib,Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 114606 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR